Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
Claim review
Tesamorelin metabolic stack — claim review
Tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. Off-label, it is promoted in 'metabolic stacks' for cosmetic visceral-fat reduction, often paired with semaglutide. This page covers what the licensed indication actually shows vs the off-label marketing leap.
What people claim
- “Targeted visceral fat reduction”
- “Preserves lean mass while semaglutide reduces fat”
- “Cosmetic body-recomposition with no insulin-sensitivity penalty”
Evidence honestly
Tesamorelin in HIV-associated lipodystrophy: published trial evidence supports the licensed indication. Off-label cosmetic-fat-loss use in non-HIV populations: limited evidence; long-term oncology surveillance in non-HIV use is essentially absent.
Combined use with semaglutide: no published RCT of the combination for either body-recomposition or metabolic outcomes.
Safer alternatives
- Licensed Wegovy / Mounjaro via NHS or GMC-registered prescriber.
- Structured resistance training to preserve lean mass during fat loss.
- Adequate protein intake (1.6-2.2 g/kg).
Frequently asked questions
- What is tesamorelin licensed for?
- FDA-approved as Egrifta for HIV-associated lipodystrophy in the US. Not MHRA-licensed in the UK. The licensed indication is narrow — it does not translate automatically to off-label cosmetic visceral-fat use.
- Does it reduce visceral fat in healthy adults?
- Trial data for cosmetic-fat-loss in non-HIV populations are sparse. The licensed-indication weight-loss signal does not necessarily generalise. Long-term safety in off-label use is uncharacterised.
- Is it WADA-prohibited?
- Yes. Tesamorelin is a GHRH analogue and falls under WADA S2 prohibited substances. Strict-liability rules apply for athletes.
- Why is it marketed in 'metabolic stacks'?
- Combined with GLP-1 agents (semaglutide), tesamorelin is marketed as 'preserving lean mass during fat loss'. The combination has no controlled human trial support and engages the same UK regulatory concerns as any unlicensed combination.
- What is the lawful UK alternative?
- For weight management: licensed Wegovy or Mounjaro via NHS or GMC-registered prescriber. For genuine HIV-lipodystrophy: specialist HIV-medicine pathway via NHS.